Freeline To Participate In Conferences During January 2022
January 04, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative...
Freeline Announces 2022 Corporate Priorities and Guidance
December 13, 2021 17:40 ET
|
Freeline Therapeutics
Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by Freeline’s differentiated platform Data...
Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial
December 13, 2021 09:01 ET
|
Freeline Therapeutics
B-AMAZE long-term follow up data demonstrate sustained FIX expression up to 3.5 years; potential for expression levels in the normal range with relatively low vector doses B-LIEVE trial to...
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
December 09, 2021 07:05 ET
|
uniQure Inc.
~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single...
Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results
November 09, 2021 16:01 ET
|
Freeline Therapeutics
Lowest dose cohort of MARVEL-1 trial of FLT190 for Fabry disease demonstrates durable α-Gal A expression over two years in the first patient and promising efficacy with near normal α-Gal A levels in...
Freeline Therapeutics to Present FLT180a Data at the 2021 ASH Annual Meeting
November 04, 2021 09:01 ET
|
Freeline Therapeutics
LONDON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
July 02, 2021 09:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update
June 22, 2021 11:31 ET
|
uniQure Inc.
~ Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in full study population one year following a single administration of etranacogene dezaparvovec ~ ~...
Revolutionary Treatment for Hemophilia B Shows Promise in Clinical Trials
May 17, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA , May 17, 2021 (GLOBE NEWSWIRE) -- Revolutionary Treatment for Hemophilia B Shows Promise in Clinical Trials Novel Hemophilia B pipeline therapeutics include SIG-003, CB 2679d-GT, ...
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
May 13, 2021 07:00 ET
|
uniQure Inc.
~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~ ~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients -- ...